Bristol-Myers pays $300 million for Cambridge biotech

Bristol-Myers pays $300 million for Cambridge biotech


Drug giant Bristol-Myers Squibb Co. has agreed to pay $300 million to buy a two-year-old Cambridge biotech that's developing treatments for cancers and other diseases.



from Biotech News